Advertisement

The Role of Metalloproteinases in Corona Virus Infection

  • Norman W. Marten
  • Jiehao Zhou
Chapter

Abstract

Infection with neurotropic strains of mouse hepatitis virus (MHV) results in rapid leukocyte infiltration into the central nervous system (CNS). The inflammatory response controls virus replication but fails to mediate sterile clearance. The persistence of viral RNA and inflammatory cells within the CNS is associated with the development of ongoing demyelination. Matrix metalloproteinases (MMPs) are a family of proteases involved in degradation of the extracellular matrix (ECM). During inflammatory responses MMPs are thought to play a significant role in breaking down the basement membrane surrounding blood vessels as well as parenchymal ECM thereby facilitating leukocyte infiltration. MMPs have also been associated with activation of chemokines and perhaps more significantly the degradation of myelin proteins and generation of autoantigens. Recent examination of MMP expression during MHV infection suggests that MMP-3, -9 and -12 are involved in the inflammatory response. The proinflammatory effects of these MMPs are likely tempered by induction of tissue inhibiter of metalloproteinase-1 expression.

Key words

Central nervous system (CNS) demyelination matrix metalloproteinase (MMP) mouse hepatitis virus tissue inhibiter of matrix metalloproteinase (TIMP) 

References

  1. 1.
    Allport, J.R., Lim, Y.C., Shipley, J.M., Senior, R.M., Shapiro, S.D., Matsuyoshi, N., Vestweber, D., and Luscinskas, F.W. Neutrophils from MMP-9-or neutrophil elastase-deficient mice show no defect in transendothelial migration under flow in vitro. J. Leukoc. Biol. 2002; 71:821.PubMedGoogle Scholar
  2. 2.
    Anthony, D. C, Ferguson, B., Matyzak, M.K., Miller, K.M., Esiri, M.M., and Perry, V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 1997; 23:406.PubMedCrossRefGoogle Scholar
  3. 3.
    Asahi, M, Wang, X., Mori, T., Sumii, T., Jung, J.C., Moskowitz, M.A., Fini, M.E., and Lo, E.H. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 2001; 21:7724.PubMedGoogle Scholar
  4. 4.
    Birkedal-Hansen, H., Moore, W. G., Bodden, M.K., Windsor, L.J., Birkedal-Hansen B., DeCarlo, A., and Engler, J.A. Matrix Metalloproteinases: a review. Crit. Rev. Oral. Biol. Med. 1993; 4:197.PubMedGoogle Scholar
  5. 5.
    Bond, M., Fabunmi, R.P., Baker, A.H., and Newby, A.C. Synergistic upregulation of Metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kB. FEBS Lett. 1998; 435:29.PubMedCrossRefGoogle Scholar
  6. 6.
    Bond, M., Baker, A.H., and Newby, A.C. Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and-3 upregulation in rabbit dermal fibroblasts. Biochem. Biophys. Res. Commun. 1999; 264:561.PubMedCrossRefGoogle Scholar
  7. 7.
    Brew, K., Dinakarpandian, D., and Nagase, H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta. 2000; 1477:267.PubMedGoogle Scholar
  8. 8.
    Chandler, S., Cossins, J., Lury, J., and Wells, G. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem. Biophys. Res. Commun. 1996; 228:421.PubMedCrossRefGoogle Scholar
  9. 9.
    Chandler S., Coates, R., Gearing, A., Lury, J., Wells, G., and Bone, E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 1995; 201:223.PubMedCrossRefGoogle Scholar
  10. 10.
    Clements J.M., Cossins, J.A., Wells, G.M., Corkill, D.J., Helfrich, K., Wood, L.M., Pigott, R., Stabler, G., Ward, G.A., Gearing, A.J., and Miller, K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 1997; 74:85.PubMedCrossRefGoogle Scholar
  11. 11.
    Cossins, J.A., Clements, J.M., Ford, J., Miller, K.M., Pigott, R., Vos, W., Van der Valk, P., and De Groot, C.J. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta. Neuropathol. 1997; 94:590.PubMedCrossRefGoogle Scholar
  12. 12.
    Cross, A.K., and Woodroofe, M.N. Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia 1999; 28:183.PubMedCrossRefGoogle Scholar
  13. 13.
    Cuzner, M.L. and Opdenakker, G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 1999; 94:1.PubMedCrossRefGoogle Scholar
  14. 14.
    Dubois, B., Masure, S., Hurtenbach, U., Paemen, L., Heremans, H., van den Oord, J., Sciot, R., Meinhardt, T., Hammerling, G., Opdenakker, G., and Arnold, B. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 1999; 104:1507.PubMedGoogle Scholar
  15. 15.
    Edwards, J.A., Denis, F., and Talbot, P.J. Activation of glial cells by human coronavirus OC43 infection. J. Neuroimmunol. 2000; 108:73.PubMedCrossRefGoogle Scholar
  16. 16.
    Giannelli G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W.G., and Quaranta, V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997; 277:225.PubMedCrossRefGoogle Scholar
  17. 17.
    Gijbels, K., Galardy, R.E., and Steinman, L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 1994; 94:2177.PubMedGoogle Scholar
  18. 18.
    Goetzl, E.J., Banda, M.J., and Leppert, D. Matrix metalloproteinases in immunity. J. Immunol. 1996; 156:1.PubMedGoogle Scholar
  19. 19.
    Gottschall, P.E. and Yu, X. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J. Neurochem. 1995; 64:1513.PubMedCrossRefGoogle Scholar
  20. 20.
    Hartung, H.P., and Kieseier, B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 2000; 107:140.PubMedCrossRefGoogle Scholar
  21. 21.
    Hewson, A.K., Smith, T., Leonard, J.P., and Cuzner, M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 1995; 44:345.PubMedCrossRefGoogle Scholar
  22. 22.
    Horton, W.E., Jr., Udo, I., Precht, P., Balakir, R., and Hasty, K. Cytokine inducible matrix metalloproteinase expression in immortalized rat chondrocytes is independent of nitric oxide stimulation. In Vitro Cell. Dev. Biol. Anim. 1998; 34:378.CrossRefGoogle Scholar
  23. 23.
    Johansson, N., Ahonen, M., and Kahari, V.M. Matrix metalloproteinases in tumor invasion. Cell. Mol. Life. Sci. 2000; 57:5.PubMedCrossRefGoogle Scholar
  24. 24.
    Kleiner, D.E. Jr and Stetler-Stevenson, W.G. Structural biochemistry and activation of matrix metalloproteases. Curr. Opin. Cell. Biol. 1993; 5:891.PubMedCrossRefGoogle Scholar
  25. 25.
    Konttinen, Y.T., Ainola, M., Valleala, H., Ma, J., Ida, H., Mandelin, J., Kinne, R.W., Santavirta, S., Sorsa, T., Lopez-Otin, C, and Takagi, M. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. 1999; 58:691.PubMedGoogle Scholar
  26. 26.
    Leco, K.J., Hayden, L.J., Sharma, R.R., Rocheleau, H., Greenberg, A.H., and Edwards, D.R. Differential regulation of TIMP-1 and TIMP-2 mRNA expression in normal and Ha-ras-transformed murine fibroblasts. Gene. 1992; 117:209.PubMedCrossRefGoogle Scholar
  27. 27.
    Lichtinghagen, R., Seifert, T., Kracke, A., Marckmann, S., Wurster, U., and Heidenreich, F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J. Neuroimmunol. 1999; 99:19.PubMedCrossRefGoogle Scholar
  28. 28.
    Liedtke, W., Cannella, B., Mazzaccaro, R.J., Clements, J.M., Miller, K.M., Wucherpfennig, K.W., Gearing, A.J., and Raine, C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 1998; 44:35.PubMedCrossRefGoogle Scholar
  29. 29.
    Liu, Z., Shipley, J.M., Vu, T.H., Zhou, X., Diaz, L.A., Werb, Z., and Senior, R.M. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J. Exp. Med. 1998; 188:475.PubMedCrossRefGoogle Scholar
  30. 30.
    Ma, Z., Qin, H., and Benveniste, E.N. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J. Immunol. 2001; 167:5150.PubMedGoogle Scholar
  31. 31.
    Madtes, D.K., Elston, A.L., Kaback, L.A., and Clark, J.G. Selective induction of tissue inhibitor of metalloproteinase-1 in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 2001; 24:599.PubMedGoogle Scholar
  32. 32.
    Maeda, A. and Sobel, R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 1996; 55:300.PubMedCrossRefGoogle Scholar
  33. 33.
    Marten, N.W., Stohlman, S.A., and Bergmann, C.C. MHV infection of the CNS: mechanisms of immune-mediated control. Viral. Immunol. 2001; 14:1.PubMedCrossRefGoogle Scholar
  34. 34.
    Nagase, H. and Woessner, J. F., Jr. Matrix metalloproteinases. J. Biol. Chem. 1999; 274:21491.PubMedCrossRefGoogle Scholar
  35. 35.
    Opdenakker, G., Van den Steen, P. E., Dubois, B., Nelissen, I., Van Coillie, E., Masure, S., Proost, P., and Van Damme, J. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 2001; 69:851.PubMedGoogle Scholar
  36. 36.
    Opdenakker, G., Van den Steen, P.E., and Van Damme, J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001; 22:571.PubMedCrossRefGoogle Scholar
  37. 37.
    Ozenci, V., Kouwenhoven, M., Teleshova, N., Pashenkov, M., Fredrikson, S., and Link, H. Multiple sclerosis: pro-and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol. 2000; 108:236.PubMedCrossRefGoogle Scholar
  38. 38.
    Pagenstecher, A., Stalder, A.K., Kincaid, C.L., Shapiro, S.D., and Campbell, I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 1998; 152:729.PubMedGoogle Scholar
  39. 39.
    Proost P., Van Damme, J., and Opdenakker, G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem, Biophys. Res. Commun. 1993; 192:1175.CrossRefGoogle Scholar
  40. 40.
    Reis, C. and Petrides, P.E. cytokine regulation of Matrix Metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe-Seyler. 1995; 376:345.Google Scholar
  41. 41.
    Rudolph-Owen, L.A., Hulboy, D.L., Wilson, C.L., Mudgett, J., and Matrisian, L.M. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology. 1997;138:4902.PubMedCrossRefGoogle Scholar
  42. 42.
    Sato, H., Takino, T., Kinoshita, T., Imai, K., Okada, Y., Stetler Stevenson, W.G., and Seiki, M. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett. 1996; 385:238.PubMedCrossRefGoogle Scholar
  43. 43.
    Stohlman, S.A., Bergmann, C.C., and Perlman, S. Mouse hepatitis virus. In Persistent Viral Infections, Vol. 26. p. 537. R. A. a. I. Chen, ed. John Wiley & Sons, 1999.Google Scholar
  44. 44.
    Strongin, A.Y., Collier, I., Bannikov, G., Marmer, B.L., Grant, G.A., and Goldberg, G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 1995; 270:5331.PubMedCrossRefGoogle Scholar
  45. 45.
    Stuve, O., Dooley, N.P., Uhm, J.H., Antel, J.P., Francis, G.S., Williams, G., and Yong, V.W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996; 40:853.PubMedCrossRefGoogle Scholar
  46. 46.
    Trojano, M., Avolio, C., Liuzzi, G.M., Ruggieri, M., Defazio, G., Liguori, M., Santacroce, M.P., Paolicelli, D., Giuliani, F., Riccio, P., and Livrea, P. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology. 1999; 53:1402.PubMedGoogle Scholar
  47. 47.
    Uhm, J.H., Dooley, N.P., Oh, L.Y., and Yong, V.W. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia. 1998; 22:53.PubMedCrossRefGoogle Scholar
  48. 48.
    Van den Steen, P.E., Proost, P., Wuyts, A., Van Damme, J., and Opdenakker, G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 2000; 96:2673.PubMedGoogle Scholar
  49. 49.
    Vissers, M.C., Winterbourn, C.C. Gelatinase contributes to the degradation of glomerular basement membrane collagen by human neutrophils. Coll. Relat. Res. 1988; 8:113.PubMedGoogle Scholar
  50. 50.
    Yong, V.W., Krekoski, C.A., Forsyth, P.A., Bell, R., and Edwards, D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998; 21:75.PubMedCrossRefGoogle Scholar
  51. 51.
    Zhou, J., Stohlman, S.A., Atkinson, R., Hinton, D.R., and Marten, N.W. Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection. J. Virol. 2002; 76:7374.PubMedCrossRefGoogle Scholar
  52. 52.
    Zhou, J., Stohlman, S.A., Hinton, D.R., and Marten, N.W. Neutrophils modulate inflammation during viral induced encephalitis. In press.Google Scholar
  53. 53.
    Zhou, J., Stohlman, S.A., Marten, N.W., Hinton, D.R. Regulation of matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinase (TIMP) genes during JHMV infection of the central nervous system. Adv. Exp. Med. Biol. 2001; 494:329.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Norman W. Marten
    • 1
  • Jiehao Zhou
    • 1
  1. 1.Keck School of MedicineUniversity of Southern CaliforniaLos Angeles

Personalised recommendations